Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Noel F.C.C. de Miranda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6122-1024; OpenAlex author ID A5065573589. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 5 papers · 2023: 1 paper · 2024: 1 paper

Papers 10

  1. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-330480↗
  2. B cell immune profiles in dysbiotic vermiform appendixes of pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2023.1230306↗
  3. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I stud… Co-author DOI 10.1016/j.ejca.2022.03.015↗
  4. The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer. Co-author DOI 10.1097/cad.0000000000001283↗
  5. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical mode… Co-author DOI 10.1136/gutjnl-2021-324834↗
  6. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry. Last author DOI 10.1136/jitc-2022-004638↗
  7. A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer. Last author DOI 10.3390/cancers14163862↗
  8. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Last author DOI 10.1007/s13402-021-00587-z↗
  9. The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers13225789↗
  10. Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis. Co-author DOI 10.1038/bjc.2013.486↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alexander L. Vahrmeijer · 5 shared papers, 2021–2022 · strength 0.86
  2. Thomas P. Brouwer · 4 shared papers, 2021–2022 · strength 0.67
  3. Casper H.J. van Eijck · 3 shared papers, 2022–2024 · strength 0.47
  4. Ricki T. Krog · 3 shared papers, 2021–2023 · strength 0.47
  5. Bert A. Bonsing · 3 shared papers, 2022 · strength 0.45
  6. Bas Groot Koerkamp · 2 shared papers, 2023–2024 · strength 0.36
  7. Dana A. M. Mustafa · 2 shared papers, 2022–2024 · strength 0.33
  8. Hans Morreau · 3 shared papers, 2013–2022 · strength 0.32
  9. Casper W.F. van Eijck · 1 shared paper, 2024 · strength 0.22
  10. Geertjan van Tienhoven · 1 shared paper, 2024 · strength 0.22
  11. Núria Malats · 1 shared paper, 2024 · strength 0.22
  12. Nigel G. Kooreman · 1 shared paper, 2021 · strength 0.19
  13. Frederike Dijk · 1 shared paper, 2022 · strength 0.15
  14. Peter D. Katsikis · 1 shared paper, 2023 · strength 0.14
  15. Eveline E. Vietsch · 1 shared paper, 2023 · strength 0.14
  16. Marcella Willemsen · 1 shared paper, 2023 · strength 0.14
  17. Roeland F. de Wilde · 1 shared paper, 2023 · strength 0.14
  18. Mark J.A. Schoonderwoerd · 1 shared paper, 2022 · strength 0.13
  19. Lukas J.A.C. Hawinkels · 1 shared paper, 2022 · strength 0.13
  20. Alfred C.O. Vertegaal · 1 shared paper, 2022 · strength 0.13
  21. Sumit Kumar · 1 shared paper, 2022 · strength 0.13
  22. Willem de Koning · 1 shared paper, 2022 · strength 0.12
  23. Sai Ping Lau · 1 shared paper, 2022 · strength 0.12
  24. Leonoor V. Wismans · 1 shared paper, 2022 · strength 0.12
  25. Michail Doukas · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.